evipedia.ai
← Back

Andrographis for Health & Longevity

Evidence Review created on 09/05/2026 using AI4L / Opus 5

Also known as: Andrographis paniculata, Andrographolide, Kalmegh, Kalmegha, King of Bitters, Chuan Xin Lian, Green Chiretta, Indian Echinacea, Creat, Sambiloto

Motivation

Andrographis is a bitter-tasting leafy plant long grown across South and Southeast Asia, where its dried leaves have been brewed and swallowed for fever and chest complaints. Its best-studied component is a plant chemical that dampens the body’s inflammatory signaling. That single property is why a herb best known as a cold remedy keeps appearing in longevity discussions, where lowering long-running inflammation is a central goal.

The plant carries the nickname “king of bitters,” and it has been a household remedy in India, China and Thailand for centuries. It moved into modern research in Scandinavia and Chile in the 1990s, and standardized extracts are now sold worldwide. Interest widened further when governments in Asia added it to national treatment lists during recent respiratory outbreaks, which pushed both sales and study numbers sharply upward.

This review examines what controlled human trials, safety analyses and product testing show about Andrographis: which effects hold up, how large they are, where the evidence is thin or contradictory, what harms have been recorded, and how the herb is dosed and monitored in practice.

Benefits - Risks - Protocol - Conclusion

This section collects high-level overviews of Andrographis written for a non-specialist or clinically literate reader.

Content from four of the six priority platforms could not be found. Searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com and lifespan.io — both by web search and by platform-targeted query — returned no article, episode or commentary discussing Andrographis or andrographolide by name. Andrographis sits in the acute-infection literature rather than the geroscience literature those platforms cover, so its absence there is expected rather than an oversight.

Grokipedia

  • Andrographis paniculata

    The dedicated primary page for the plant, covering botany, phytochemistry, traditional use and the modern clinical record in one continuous entry rather than as scattered mentions.

Examine

  • King of Bitters

    Grades seven trials in 952 participants by outcome, and is unusually direct about the core confound: much of the human evidence tested Andrographis combined with Eleutherococcus senticosus rather than alone.

ConsumerLab

  • Andrographis for Colds, Arthritis and More

    The only source here reporting independent laboratory testing of retail products: its January 2026 update found seven of ten andrographis supplements below label claim and one containing none. ConsumerLab sells subscriptions, not supplements.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that pool the human trial evidence on Andrographis, covering both its claimed effect and its principal risk.

Both sides of the central trade-off are represented: the claimed effect on respiratory symptoms is covered by three of these reviews, and the principal risk — adverse events, including fatal anaphylaxis with injectable derivatives — is covered by two dedicated safety meta-analyses.

Mechanism of Action

Andrographis acts mainly through andrographolide, a bitter diterpene lactone that makes up roughly 1–3% of the dried leaf and up to 30% of concentrated extracts. Its best-characterized action is covalent binding to NF-κB (nuclear factor kappa B, a master switch that turns on inflammatory genes), which suppresses transcription of tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), both inflammatory messenger proteins. In parallel it activates Nrf2 (a transcription factor that switches on the cell’s own antioxidant defenses).

A newer, competing account places the primary action upstream in metabolism: andrographolide restrains glycolysis (the breakdown of sugar for energy) in activated immune cells, and the anti-inflammatory effect follows from that fuel restriction rather than from direct gene-switch binding. Both readings are actively argued in the literature.

The molecule is promiscuous rather than selective, engaging several transcription factors and kinases at similar concentrations; tissue distribution is wide but brain penetration is limited. Pharmacologically it is absorbed quickly but poorly. Peak plasma levels after an oral extract sit in the microgram-per-litre range, and doubling the dose does not double exposure — oral bioavailability is non-linear. The elimination half-life is short, roughly two to six hours, which is why protocols split the daily dose. Clearance is dominated by phase II conjugation (sulfation and glucuronidation, the liver’s tagging reactions) rather than by cytochrome P450 (CYP450, the liver’s main drug-oxidizing enzyme family) oxidation; gut bacteria add a sulfonation step that further lowers systemic exposure.

Historical Context & Evolution

Andrographis entered written medicine as a fever remedy. Ayurvedic texts list it as kalmegh and Chinese materia medica as chuan xin lian; in both traditions the dried aerial parts were decocted for acute febrile illness, dysentery and snakebite. Colonial Indian pharmacopoeias carried it as a bitter tonic and as a substitute antimalarial when quinine ran short. A widely repeated claim that it curbed the 1919 influenza epidemic in India circulates without a primary source and is best read as folklore rather than evidence.

The modern research line begins in the 1980s and 1990s on two fronts. Thai health authorities placed the crude herb on the national essential medicines list for pharyngitis and diarrhea, prompting hospital trials in Bangkok in pharyngotonsillitis (infection of the throat and tonsils). In parallel, the Swedish Herbal Institute standardized a leaf extract and combined it with Eleutherococcus senticosus, and a Chilean pharmacology group at Universidad Austral de Chile isolated andrographolide as the active principle.

The shift toward health optimization was mechanistic rather than clinical. Once andrographolide was shown to suppress inflammatory gene transcription, the herb was reframed from an anti-infective into a broad anti-inflammatory, and trials moved to arthritis, colitis and multiple sclerosis. That reframing is not settled. Whether the respiratory benefit is antiviral, anti-inflammatory or largely symptomatic remains open, and the infection-era data have not been overturned so much as left unrepeated at modern methodological standards.

Expected Benefits

High 🟩 🟩 🟩

Faster Resolution of Acute Respiratory Infection Symptoms

Andrographis shortens and softens the symptoms of colds, sore throat and acute bronchitis. The likely mechanism is suppression of the symptom-generating inflammatory response rather than direct virus killing. The evidence base is a meta-analysis of 33 randomized controlled trials (RCTs — studies in which participants are assigned by chance to treatment or placebo) in 7,175 patients, supported by an earlier systematic review of seven double-blind trials. Trial quality was rated poor overall, many trials tested fixed herbal combinations, and most branded-product trials were run by the extract manufacturers.

Magnitude: Pooled standardized mean difference (SMD — effect size expressed in standard-deviation units) versus placebo was −1.13 (95% CI, or confidence interval, the range within which the true value most likely lies: −1.37 to −0.89) for sore throat and −0.39 (−0.67 to −0.10) for cough.

Medium 🟩 🟩

Knee Osteoarthritis Pain and Function

Standardized andrographolide extract reduced knee pain, stiffness and physical-function scores on the WOMAC index (a validated osteoarthritis questionnaire) in 103 adults with mild-to-moderate disease. The proposed mechanism is inhibition of inflammatory gene transcription in joint tissue. Evidence is a single 84-day placebo-controlled trial whose lead author is affiliated with the extract manufacturer HP Ingredients, a direct commercial interest in a positive result. A separate rheumatoid arthritis trial by the same Chilean group missed its primary pain endpoint while improving joint counts, so the joint-pain signal is real but narrow.

Magnitude: WOMAC pain fell significantly versus placebo at days 28, 56 and 84 at both 300 mg and 600 mg daily; the published report states significance without giving a between-group effect size.

Clinical Response in Active Ulcerative Colitis

A purified Andrographis extract (HMPL-004) improved clinical response in mildly to moderately active ulcerative colitis (inflammation and ulceration of the colon lining). The mechanism is suppression of tumor necrosis factor alpha and interleukin-1 beta in gut mucosa. Evidence is one 224-patient placebo-controlled trial positive at the higher dose only, plus a 120-patient trial finding it comparable to mesalazine. Both were sponsored by the developer, Hutchison Medipharma. The subsequent phase III programme was stopped for futility, with results posted only to the registry, which weakens the case considerably.

Magnitude: 60% clinical response at 1,800 mg daily versus 40% on placebo at week 8 — 20 percentage points absolute, p = 0.018; remission rates did not separate from placebo.

Reduced Fatigue and Disability Measures in Multiple Sclerosis

Andrographis reduced fatigue in relapsing-remitting multiple sclerosis (a disease in which the immune system attacks nerve insulation) and, in a separate trial in progressive disease, slowed loss of brain volume and disability worsening. The proposed mechanism is reduced central inflammation. Evidence is two small placebo-controlled trials, 22 and 44 patients, run by the Chilean group that developed the extract. Both are underpowered pilots; the brain-atrophy endpoint missed significance, and only the disability scale separated.

Magnitude: 44% reduction in Fatigue Severity Scale score at 12 months versus placebo; in progressive disease, mean disability-scale change was −0.025 with Andrographis against +0.352 with placebo (p = 0.042).

Triglyceride Lowering in Hypertriglyceridemia

In adults with raised blood triglycerides — the main fat carried in blood, and a cardiovascular risk factor — an Andrographis extract standardized to about 120 mg andrographolide daily lowered triglycerides over eight weeks to a degree comparable with gemfibrozil, a standard triglyceride-lowering drug. Evidence is one 60-person three-arm trial with lifestyle advice given to all groups. The lower extract dose did nothing, the study had no placebo arm, and the result has not been replicated.

Magnitude: Triglycerides fell 41.6 ± 86.3 mg/dL from baseline on the higher extract dose (p = 0.044), against 57.1 ± 94.9 mg/dL on gemfibrozil 300 mg daily.

Low 🟩

Fewer Colds During Prophylactic Use

Taken continuously through winter rather than at symptom onset, Andrographis appeared to lower the number of colds caught. Evidence is one randomised placebo-controlled pilot in schoolchildren testing Kan Jang tablets made from dried Andrographis extract, plus a preventive signal in an early systematic review. Indirect and never replicated.

Magnitude: Cold incidence over three winter months was 30% (16 of 54) on Andrographis versus 62% (33 of 53) on placebo — a relative risk of catching a cold 2.1 times lower (95% CI 1.32–3.33); no separation appeared before month three.

Reduction of Circulating Inflammatory Markers in Acute Viral Illness ⚠️ Conflicted

One randomized trial in mild COVID-19 found interleukin-1 beta consistently lower with Andrographis added to antiviral therapy. A 2025 meta-analysis of six trials found no difference in C-reactive protein or interleukin-6, both general markers of inflammation. Net reading: any marker effect is small, inconsistent and not tied to clinical benefit.

Magnitude: Pooled mean difference versus comparator was −0.04 (95% CI −0.26 to 0.18) for C-reactive protein and −0.07 (−0.17 to 0.03) for interleukin-6 — neither significant.

Slowed Decline in Advanced Esophageal Cancer

A concentrated Andrographis water extract was used as palliative care in metastatic esophageal squamous cell carcinoma. Evidence is a single-arm phase II study in 30 patients, with no placebo group. Survival was compared between those who completed four months and those who stopped early, a confounded contrast.

Magnitude: Direction is longer overall survival with quality of life maintained, seen only in the ten patients who finished the full four-month course; the published report states significance without giving a survival figure or hazard ratio (a measure of how much faster or slower an event occurs in one group than the other).

Speculative 🟨

Protection of Lung Tissue Against Smoke and Pollutant Injury

Andrographolide preserved lung antioxidant defenses and reduced airway inflammation in cigarette-smoke-exposed mice by raising Nrf2 activity. The basis is animal and cell work only; no human lung-function outcome has been measured.

Preservation of Brain Glucose Handling and Memory

In Alzheimer’s-model mice, andrographolide restored neuronal glucose uptake and improved memory behavior; a derivative repeated this in mice carrying the human APOE4 variant, which raises dementia risk. Basis is animal work only.

Protection Against Cholestatic Liver Injury

In mice, andrographolide reduced cholestatic liver injury (damage from bile backing up in the liver) by switching on the bile-acid receptor FXR. Basis is animal work only; no human liver outcome exists.

Lowering of Blood Glucose

Andrographolide improved glucose tolerance and insulin resistance in diabetic mice by tightening the gut barrier. Basis is animal and cell work only; no controlled human glucose trial exists.

Benefit-Modifying Factors

  • Genetic variation in conjugating enzymes: No validated pharmacogenetic marker exists. Andrographolide is cleared by sulfotransferases and UGT enzymes (which attach sugar or sulfate groups to speed elimination), so common variants in those families are the plausible candidates rather than the usual CYP450 ones.

  • Gut microbiome composition: Intestinal bacteria convert andrographolide into an inactive sulfonate before absorption. A conversion-heavy microbiome measurably lowers systemic exposure, which is one likely reason response varies so widely between individuals given identical doses.

  • Baseline inflammatory burden: Benefit tracks how much inflammation there is to suppress. Trials in active colitis, arthritis and acute infection show separation from placebo; no trial has shown benefit in people with normal baseline C-reactive protein and no symptoms.

  • Timing relative to symptom onset: For respiratory illness the window is narrow. Started within 36–48 hours of first symptoms, the effect is measurable; started later, the illness is already resolving on its own and the herb has little left to shorten.

  • Sex: Trials enrolled both sexes and no sex-stratified efficacy analysis has been published for any indication. The only sex-specific human finding concerns male reproductive safety, not efficacy, so any sex difference in benefit is currently undocumented.

  • Pre-existing health conditions: Autoimmune and inflammatory disease is where the herb performs. Multiple sclerosis, rheumatoid arthritis and ulcerative colitis trials all show signal; the metabolic finding is confined to people whose triglycerides were already elevated at entry.

  • Age: Trials skew to adults aged 18–60, and the osteoarthritis trial extended to 85. Older adults with more inflammation may gain more, but no trial has reported age-stratified results, so this remains extrapolation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset

The most frequently recorded adverse effect is gastrointestinal: nausea, abdominal discomfort, loose stools and heartburn, driven partly by the extreme bitterness of the herb and partly by direct mucosal irritation. The evidence base is a meta-analysis pooling ten randomized trials and three intensive-monitoring studies, plus adverse-event tables across the respiratory trials. Effects are mild, dose-related and reverse on stopping. They are among the main reasons participants withdraw from longer trials.

Magnitude: Pooled incidence of non-serious adverse events was 102.6 per 1,000 patients (95% CI 10.7–256.1) in randomized trials and 34.2 per 1,000 (0.0–229.6) under intensive monitoring, with gastrointestinal complaints the largest category.

Hypersensitivity Reactions Including Anaphylaxis

Skin and subcutaneous reactions — rash, itching and hives — are the second most common adverse-event category, and were recorded in both the relapsing-remitting and progressive multiple sclerosis trials. The serious end of the spectrum is anaphylaxis, documented overwhelmingly with injectable andrographolide derivatives used in China rather than with oral herbal preparations. Guinea-pig and mast-cell testing found no anaphylactic potential for whole extract while isolated andrographolide released allergic mediators in cell culture, so the responsible constituent is unresolved.

Magnitude: Across 9,490 recipients of injectable andrographolide derivatives, 383 (4.04%) reported adverse drug reactions; 55 experienced anaphylactic shock and three deaths were attributed to the injection. Oral herbal preparations produced only mild-to-moderate skin and gastrointestinal reactions.

Medium 🟥 🟥

Altered Taste

Dysgeusia (a persistent distortion of taste) was one of only two adverse events attributed to the compound in the progressive multiple sclerosis trial, alongside mild rash. The mechanism is presumed direct: andrographolide is intensely bitter and lingers on oral receptors. It is not dangerous, but it is a common reason for stopping, and it was reported at 280 mg andrographolide daily taken for up to 24 months.

Magnitude: Direction is a bitter or metallic taste appearing early and persisting while dosing continues; the trial reported it qualitatively as mild and transient without publishing an incidence figure.

Low 🟥

Transient Liver-Enzyme Elevation ⚠️ Conflicted

Transaminase rises (ALT and AST — enzymes released when liver cells are stressed) were the commonest abnormality across the COVID-19 trial set. Against this, a Thai placebo-controlled trial and a pharmacokinetic study found no hepatic toxicity. Net reading: reversible enzyme drift is plausible at higher doses; sustained injury is undemonstrated.

Magnitude: Direction is upward and confined to higher-dose multi-day extract regimens taken during acute infection; the systematic review reports these events narratively and gives no pooled incidence or effect size.

Additive Bleeding Risk with Antiplatelet Drugs ⚠️ Conflicted

Andrographolide inhibits thrombin-induced platelet clumping in vitro. In ten healthy volunteers given 6 g of Andrographis in one day, platelet aggregation and clotting-activation markers did not change significantly. Net reading: a theoretical bleeding interaction with no confirmed human signal.

Magnitude: Adenosine-diphosphate-induced aggregation trended downward without reaching significance in the only human study, which enrolled ten people; no bleeding event rate has been reported.

Speculative 🟨

Male Reproductive Toxicity

High-dose andrographolide damaged rat testicular tissue and suppressed androgens in rodent studies. A human phase I study of a fixed Andrographis combination found no negative effect on semen quality.

Kidney Toxicity at Very High Doses

Toxicology reviews flag kidney injury alongside reproductive effects at doses far above human use. Rodent repeat-dose studies found no adverse effect at 1 g/kg for eight weeks.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been validated as modifying Andrographis risk. Because clearance runs through sulfation and glucuronidation rather than CYP450 oxidation, slow-conjugator phenotypes are the theoretical concern, but no genotyped safety study exists.

  • Baseline biomarker levels: Baseline transaminases set the interpretive floor for the liver signal. Someone starting with ALT already at the upper limit has no headroom to distinguish herb-related drift from their pre-existing pattern.

  • Sex: The only sex-asymmetric risk is male: rodent testicular and androgen findings have no female counterpart. No sex difference in gastrointestinal, hepatic or allergic events has been reported in any trial.

  • Pre-existing health conditions: Active liver disease, gallstones or bile-duct obstruction, bleeding disorders and autoimmune disease on immunosuppressants all raise the stakes. So does a documented plant or Acanthaceae-family allergy, given the hypersensitivity signal.

  • Age: Older adults carry more polypharmacy and lower renal and hepatic reserve, which amplifies both interaction risk and enzyme-drift significance. No trial has reported adverse events stratified by age band.

  • Route and formulation: This is the largest single risk modifier. Fatal anaphylaxis is concentrated in injectable andrographolide derivatives; oral herbal preparations carry a different and far milder event profile.

Key Interactions & Contraindications

  • Immunosuppressants and biologics (ciclosporin, tacrolimus, azathioprine, adalimumab): Caution. Andrographis suppresses inflammatory transcription and may add to immunosuppression or oppose the immune activation intended by checkpoint therapy. Mitigation is separated dosing with monitoring of disease activity.

  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin, apixaban): Caution. In vitro platelet inhibition raises a theoretical additive bleeding risk not confirmed in humans. Mitigation is withdrawal 7–14 days before elective surgery, with observation for unexplained bruising.

  • Antihypertensives (amlodipine, lisinopril, losartan): Monitor. Andrographis has been studied with blood-pressure-lowering intent, so additive hypotension is plausible. Mitigation is weekly seated blood-pressure measurement through the first month of combined use.

  • Glucose-lowering drugs (metformin, sulfonylureas, insulin): Monitor. A dedicated crossover trial exists precisely because a metformin interaction is suspected; the consequence is additive glucose lowering with hypoglycaemia (blood sugar dropping too low). Mitigation is increased glucose self-monitoring for two weeks after starting or stopping.

  • Narrow-therapeutic-index drugs cleared by UGT2B7 (morphine, zidovudine, valproate): Caution. Andrographolide derivatives are highly specific UGT2B7 inhibitors (that enzyme attaches sugar groups for excretion), so parent-drug levels may rise. Mitigation is avoidance or drug-level measurement.

  • CYP1A2, CYP2C9 and CYP3A4 substrates (theophylline, celecoxib, statins): Monitor. Inhibition of these drug-oxidizing enzymes would raise substrate levels — theophylline seizures, statin muscle injury. A review of the in vitro data found the evidence too inconsistent to call Andrographis an inhibitor. Unresolved, not excluded.

  • Over-the-counter medicines (ibuprofen, naproxen, aspirin, paracetamol): Caution. Rodent work shows altered NSAID (non-steroidal anti-inflammatory drug) pharmacokinetics with Andrographis co-dosing, and NSAIDs add their own gastric irritation. Mitigation is separating doses by two hours.

  • Supplements with additive anti-inflammatory or antiplatelet action (fish oil, curcumin, garlic, ginkgo, high-dose vitamin E, nattokinase): Caution. Each independently reduces platelet aggregation; stacking them compounds a bleeding risk none carries alone. Mitigation is limiting the stack to one such agent perioperatively.

  • Supplements with additive glucose- or lipid-lowering action (berberine, bitter melon, red yeast rice, fenugreek): Monitor. Andrographis lowered triglycerides at drug-comparable strength, so combined use can overshoot targets. Mitigation is a repeat lipid panel and fasting glucose at eight weeks.

  • Eleutherococcus senticosus: Monitor. The most-studied Andrographis product is a fixed combination with this adaptogen, so taking both separately duplicates a tested pairing; the consequence is additive immunomodulation and unintended double dosing. Mitigation is counting the combination product toward the daily total.

  • Other interventions — vaccination and elective surgery: Caution. An immunomodulating herb around vaccination has unknown directional effect on response, and the theoretical antiplatelet action matters perioperatively. Mitigation is a two-week pause before scheduled surgery.

Populations who should avoid Andrographis:

  • Pregnancy at any stage, and breastfeeding — rodent antifertility and abortifacient signals with no human safety data
  • Men actively trying to conceive, given the rodent testicular and androgen-suppression findings
  • Anyone with a prior hypersensitivity reaction to Andrographis, andrographolide or another Acanthaceae-family plant
  • Active liver disease or cholestasis (blocked bile flow) — Child-Pugh Class B or C, or transaminases above three times the upper limit of normal
  • Bleeding disorders, or within 14 days of planned surgery
  • Autoimmune disease being actively managed on immunosuppressants without prescriber oversight
  • Children under 18 outside a supervised trial protocol — trials in children used fixed combinations, not standardized single-herb extract

Risk Mitigation Strategies

  • Low starting dose held for a week: Protocols open at 200 mg standardized extract daily rather than 400–600 mg. This surfaces gastrointestinal intolerance and rash at the dose least likely to force complete discontinuation.

  • Dosing with food rather than on an empty stomach: Food buffers direct mucosal contact and blunts the nausea and heartburn behind most withdrawals. Capsule and enteric-coated forms further reduce contact with the oral and gastric lining.

  • Capping continuous use at 8–12 weeks for acute indications: Respiratory dosing is designed for 5–7 days. Extending short-course dosing indefinitely accumulates liver-enzyme and taste-disturbance exposure without a matching evidence base.

  • Transaminase testing before and during extended courses: ALT and AST drawn at baseline and again at 8–12 weeks on any course longer than a month catch asymptomatic enzyme drift before it becomes a clinical event.

  • Restriction to oral preparations: The fatal anaphylaxis record belongs almost entirely to injectable andrographolide derivatives. Confining use to oral extract removes the single most severe documented harm from the risk profile.

  • Discontinuation at the first rash, itch or facial swelling: Skin reactions are the visible early edge of the hypersensitivity spectrum. Stopping at that point, rather than dose-reducing, prevents progression toward systemic allergic reaction.

  • A 14-day pause before surgery or invasive dental work: This clears any theoretical additive antiplatelet effect well beyond the compound’s short half-life and removes an avoidable perioperative bleeding variable.

Therapeutic Protocol

  • Standard acute respiratory dose: 200 mg standardized extract daily, or 400 mg three times daily of a lower-strength extract, for 5–7 days, started within 36–48 hours of first symptoms. This is the dose range used across the trial set.

  • Standard inflammatory-condition dose: 300–600 mg daily of extract standardized to 30% andrographolides for joint conditions; 280–340 mg andrographolide daily in the multiple sclerosis trials; 1,800 mg extract daily in ulcerative colitis.

  • Competing approach — crude powder tradition: Thai and Ayurvedic practice uses 2–6 g of dried whole-herb powder daily. Crude capsules dissolve more completely than some concentrated extracts, so raw dose is a poor guide to delivered andrographolide.

  • Competing approach — fixed combination: The Swedish Herbal Institute’s Kan Jang pairs standardized extract with Eleutherococcus senticosus. Most positive respiratory trials used this format, so single-herb extract is the less-tested option despite being the more common retail one.

  • Who popularized each approach: The Swedish Herbal Institute developed the standardized combination format; HP Ingredients markets the 30%-andrographolide extract used in the Chilean trials; Hutchison Medipharma developed the purified colitis extract.

  • Best time of day: No chronobiological data exist. Trials dosed with meals two or three times daily; the practical constraint is food, not clock time, because empty-stomach dosing drives the nausea that ends most courses.

  • Half-life and dosing frequency: The two-to-six-hour elimination half-life means once-daily dosing leaves most of the day at negligible plasma levels. This is the pharmacological reason trials used two or three divided doses.

  • Single versus split dosing: Split. Oral bioavailability is non-linear, so a doubled single dose yields little extra exposure, whereas dividing the same total across the day sustains plasma concentration far more effectively.

  • Genetic polymorphisms influencing dose: None validated. No CYP-based dose adjustment applies because clearance is conjugative, and no UGT or sulfotransferase genotype has been tested against Andrographis exposure in humans.

  • Sex-based differences in dosing: No sex-specific dose has been established; trials used identical dosing for both sexes. The only sex-linked consideration is that men planning conception have a reason to avoid the compound entirely.

  • Age considerations: Trials capped enrolment at 60 in the infection studies and 85 in osteoarthritis. Protocols for adults over 70 stay at the lower end given reduced hepatic and renal reserve and higher background polypharmacy.

  • Baseline biomarkers influencing response: Elevated triglycerides and elevated inflammatory markers are the two baselines associated with measurable change. Normal baselines predict no measurable movement, which makes pre-dosing measurement worth the effort.

  • Pre-existing conditions influencing response: Active autoimmune or inflammatory disease is where response is largest. Healthy users taking it prophylactically have only the prevention pilot to rely on, which is the weakest evidence in this review.

Discontinuation & Cycling

  • Intended duration: Short-term by design. Every efficacy trial ran 5 days to 12 months with a defined endpoint; no trial has tested indefinite daily use, so lifelong dosing is unsupported rather than disproven.

  • Withdrawal effects: None documented. No trial reported rebound symptoms, discontinuation syndrome or return of disease activity above baseline after stopping, across durations from five days to two years.

  • Tapering: Not required. The short half-life and absence of receptor adaptation mean abrupt cessation is the norm in every trial protocol; no study used a taper.

  • Cycling for efficacy maintenance: No efficacy tolerance has been reported, so cycling is not needed to preserve effect. Cycling is instead a reasonable exposure-limiting habit — for example 8–12 weeks on, 4 weeks off — given the open liver question.

  • Practical stopping points: Acute courses end at symptom resolution; chronic courses without measurable benefit end at 12 weeks; rash or persistent taste disturbance ends a course immediately rather than being worked through.

Sourcing and Quality

  • Standardization is the only meaningful label claim: The informative figure is stated andrographolide or total-andrographolide percentage, not milligrams of “extract”. A 200 mg 30%-standardized capsule delivers roughly the same active load as several grams of crude powder.

  • Label accuracy is genuinely poor: Testing of 40 products from 13 countries found andrographolide content ranging from 29% to 174% of the labelled dose, with only two accurately labelled and 20 underdosed. Independent verification is not optional.

  • Contamination is a real online-purchase risk: That same analysis found mercury in one online-bought product and the pesticides strychnine and butralin in two others. Pharmacy-sourced products were cleaner than online-retail ones.

  • Third-party testing matters more here than for most supplements: The available checks are USP, NSF or Informed Choice certification, or a batch-specific certificate of analysis showing andrographolide assay plus heavy-metal and pesticide screens. Retail testing has repeatedly found products below claim.

  • Dissolution differs from content: Comparative testing showed concentrated extract capsules often dissolved worse than crude powder capsules, with only an aqueous extract releasing over 80% of all four diterpenoids within 45 minutes. Content on the label is not delivered dose.

  • Named tested formats: ParActin (HP Ingredients), KalmCold and AP-Bio (Natural Remedies) and Kan Jang (Swedish Herbal Institute) are the branded extracts with published human trials. Each manufacturer funded the trials of its own product.

Practical Considerations

  • Time to effect: Fast for infection, slow for inflammation. Respiratory symptom separation appears by day 3 and is clearest by day 5; joint pain took 28 days, fatigue took months, and triglyceride change took eight weeks.

  • Common pitfall — starting too late: The respiratory benefit depends on dosing inside the first 36–48 hours. Started on day four of a cold, the herb is competing with natural resolution and will look inert.

  • Common pitfall — dosing once daily: The short half-life makes a single daily dose pharmacologically weak. Trials that worked used two or three divided doses; retail labels frequently suggest one.

  • Common pitfall — confusing crude powder with extract: Swapping a 200 mg concentrated extract for 200 mg of powdered herb cuts the delivered andrographolide roughly tenfold. The two are not interchangeable at equal milligram weight.

  • Regulatory status: Sold as a dietary supplement in the United States and as a herbal food supplement in Europe, with no marketing authorization anywhere in the West. Thailand lists the crude herb on its national essential medicines list.

  • Cost and accessibility: Inexpensive and widely available — standardized extract typically costs less than a month of most branded supplements. Neither cost nor access is a meaningful barrier; product quality is.

  • Structural funding bias: Andrographis competes with reimbursed prescription products — mesalazine in colitis, NSAIDs in osteoarthritis. Insurers and health systems capture no revenue from an unpatentable herb, so neither payers nor manufacturers fund the head-to-head trials that would settle its place.

Interaction with Foundational Habits

  • Sleep: Indirect and mostly favourable. Andrographis has no stimulant or sedative action and no reported effect on sleep architecture; the observed benefit is removal of sleep disruption caused by cough and sore throat, which improved in the respiratory trials. Lingering bitterness makes an evening dose with food preferable to one immediately before bed.

  • Nutrition: Direct and practically important. Food buffers the gastric irritation behind most withdrawals, which is why trial protocols paired every dose with a meal. Dietary fibre and fermented foods reshape the gut bacteria that sulfonate andrographolide before absorption, meaning diet plausibly alters delivered dose. No nutrient depletion has been documented.

  • Exercise: Indirect, with a theoretical caution. No trial has tested Andrographis around training, and no effect on strength or hypertrophy has been measured. Because the compound blunts inflammatory signalling, the same theoretical concern raised for high-dose antioxidants around adaptation applies, but it is untested. Fatigue scores improved rather than worsened.

  • Stress management: Indirect. Andrographis is not itself an adaptogen and has no measured effect on cortisol or the stress axis, though it is most often sold combined with Eleutherococcus senticosus, which is. Attributing stress-related benefit to Andrographis in those combination products confuses the two ingredients.

Monitoring Protocol & Defining Success

A baseline drawn before the first dose is what makes everything after it interpretable, because Andrographis produces small changes invisible without a before-value: a liver panel anchors the enzyme question, a fasting lipid panel covers triglyceride lowering, and high-sensitivity C-reactive protein covers inflammation. Existing liver disease, anticoagulant therapy or glucose-lowering drugs additionally warrant a complete blood count and kidney function.

Ongoing testing scales with course length. A 5–7 day respiratory course warrants no laboratory follow-up. Continuous use warrants a repeat liver panel at 8–12 weeks and every 6 months thereafter, with lipids and inflammatory markers repeated at 8–12 weeks to establish whether continuing is worthwhile, then annually. Rash, jaundice (yellowing of skin or eyes) or persistent nausea are grounds for immediate discontinuation and retesting.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT (alanine aminotransferase) 10–26 U/L (men), 8–22 U/L (women) Most sensitive marker of the documented enzyme-drift signal Conventional labs flag only above 40–55 U/L; functional practitioners act far earlier. Fasting not required
AST (aspartate aminotransferase) 10–26 U/L Pairs with ALT to separate liver origin from muscle origin Conventional labs flag only above 40 U/L. Rises after hard exercise; avoid testing within 48 hours of heavy training
Total bilirubin 0.3–1.0 mg/dL Detects bile-flow impairment that transaminases alone can miss Gilbert’s syndrome (a common harmless inherited variant) raises this benignly, so an individual’s own pattern comes first
hs-CRP Below 1.0 mg/L The target the anti-inflammatory rationale rests on hs-CRP is high-sensitivity C-reactive protein, a general marker of inflammation. Conventional cardiovascular cut-off is 3.0 mg/L. Invalid within 2 weeks of any infection or injury. Best paired with fasting insulin
Fasting triglycerides Below 80 mg/dL The one metabolic endpoint with a positive human trial Conventional labs flag only above 150 mg/dL. Requires a 12-hour fast; alcohol within 72 hours inflates the result substantially
Complete blood count with differential Eosinophils below 3% of white cells Rising eosinophils are an early objective signal of allergic response Conventional labs flag only above 5%. Non-specific, so read alongside rash or itch rather than alone
eGFR Above 90 mL/min/1.73 m² Addresses the rodent kidney-toxicity signal in long-term users eGFR is estimated glomerular filtration rate, a measure of kidney filtering capacity. Conventional labs flag only below 60 mL/min/1.73 m². Creatinine-based estimates are distorted by high muscle mass; cystatin C is the better paired test
Fasting glucose 75–86 mg/dL Detects additive lowering when combined with glucose-lowering drugs Conventional reference range runs to 99 mg/dL. Only relevant for people already on such drugs. Pair with HbA1c (average blood sugar over ~3 months)
Seated blood pressure Below 120/80 mmHg Catches additive hypotension with antihypertensive drugs Measure after 5 minutes seated, same arm, same time of day

Qualitative markers matter as much as the panel, because much of what Andrographis is taken for is symptomatic.

  • Days from first symptom to full functional recovery during a respiratory illness, tracked across at least three episodes
  • Morning joint stiffness duration in minutes, recorded on waking
  • Fatigue on a consistent 0–10 scale at the same hour each day
  • Taste: any persistent bitter or metallic sensation between doses
  • Stool frequency and form, as the earliest signal of gastrointestinal intolerance
  • Skin: new itching, flushing or rash anywhere on the body

Emerging Research

  • Long-duration structural osteoarthritis trial: NCT04833946 randomized 80 adults with grade II–III knee osteoarthritis to 336 days of Andrographis extract or placebo, with magnetic resonance imaging joint-space narrowing as the primary endpoint. It completed in February 2024; no results have been posted or published.

  • Largest registered Andrographis trial, unreported: NCT05019326 planned 3,060 asymptomatic COVID-19 patients across three arms in Thailand, with hospitalization as the endpoint. Its registry status has not been updated since 2021 and no results exist, leaving the largest planned trial an open question.

  • Metabolic endpoint under study: NCT06520501 compares Andrographis herb against brisk walking on blood glucose in 30 adults with obesity. Small and registered as not yet recruiting, it would nonetheless be the first head-to-head against an exercise comparator.

  • Bioavailability is the field’s rate-limiting problem: Songvut et al., 2025 showed doubling the oral dose barely raised peak concentration, and Tang et al., 2024 identified gut-bacterial sulfonation as a cause. Reformulation work could raise or lower every effect size in this review.

  • Derivatives aimed at brain aging: Zhou et al., 2024 reported that an andrographolide derivative targeting SIRT3-FOXO3a signalling (a mitochondrial quality-control pathway) reduced cognitive impairment in mice carrying the human APOE4 variant. This is the most direct longevity-relevant line and remains entirely preclinical.

  • Evidence that could weaken the case: the 2025 COVID-19 meta-analysis was null on every clinical endpoint, and a retrospective cohort of 605 hospitalized patients found no reduction in pneumonia. Larger, better-designed trials have consistently produced smaller effects than the early literature.

  • Product-quality research as a confounder: Bourqui et al., 2025 found andrographolide content ranging from 29% to 174% of label across 40 products. If retail variability of that magnitude also affected trial materials, published effect sizes may reflect dose noise as much as pharmacology.

Conclusion

Andrographis is a bitter medicinal plant whose activity rests on a single compound that quiets the body’s inflammatory signalling. The strongest case is the oldest one: taken within the first day or two of a cold or sore throat, it measurably shortens and softens symptoms, supported by the combined results of many small trials. Beyond that, the picture thins quickly. Signals in joint pain, bowel inflammation, multiple sclerosis fatigue and blood fats each rest on one or two small trials, and the largest and most recent analyses have returned smaller effects than the early work — or none.

Side effects are the main practical limit. Stomach upset and skin reactions are common though mild, taste disturbance drives people to stop, and mild liver-enzyme rises appear at higher doses without evidence of lasting harm. The severe allergic reactions on record belong almost entirely to injected forms used in hospitals abroad, not to capsules.

Two things weigh on the evidence itself. Nearly every positive trial of a named product was funded or led by the company selling it, and independent testing has found retail products routinely below label and occasionally contaminated. Because no insurer or health system profits from an unpatentable herb, well-funded independent trials have not followed. What remains is a cheap, short-acting plant with one modest well-supported use and a long list of plausible but unproven others.

Top - Benefits - Risks - Protocol